Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has successfully transferred the technology for the manufacture of Iomaba -B , a drug being developed for therapeutic treatment of incurable blood cancers.
http://www.businesswire.com/news/topix/20131219005219/en
http://www.businesswire.com/news/topix/20131219005219/en
No comments:
Post a Comment